A draft guidance issued by the US Food and Drug Administration regarding fecal microbiota transplants may affect how stool banks operate.
At the Personalized Medicine World Conference, researchers talked about how understanding the microbiome is leading to therapies aimed at keeping it healthy.
The company plans to add assays for Group B Streptococcus, Clostridium difficile, and norovirus in 2016 to complement its existing meningitis test.
Wells Fargo downgraded Cepheid from Outperform to Market Perform, citing the firm's "credibility and visibility" following a revised 2017 outlook.
The Quebec City, Canada-based firm will launch its point-of-care molecular platform with GBS and C. diff tests next year as CE-IVD products.
The Austin, Texas-based molecular diagnostics firm logged $60.6 million in Q3 revenues as its system sales shot up 26 percent to $9.6 million.
The results confirm previous findings suggesting molecular tests may not be the best tool guide treatment for Clostridium difficile infection, and toxin assays are necessary.
Using Quanterix's Simoa technology, the group developed assays to detect C. diff toxins with a high degree of sensitivity and specificity.
The assay is the first on the firm's isothermal nucleic acid amplification-based platform.
The test adds to a growing menu of approved assays for the cobas 4800 system.
A New Zealand minister says the country's genetic modification laws need to be re-examined to help combat climate change, the New Zealand Herald reports.
A new analysis finds some cancers receive more nonprofit dollars than others.
An Australian mother's conviction in the deaths of her children may be re-examined after finding that two of the children carried a cardiac arrhythmia-linked gene variant.
In Science this week: comparative analysis of sex differences in mammal gene expression, and more.